TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05833113

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, 50 mm block needle will be advanced through the interscalene groove. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area.~The control group will also receive the TENS-pants electrodes, connected to TENS treatment. In the placebo-TENS applications on the painful area, 2 channels with 4 electrodes in the acute period will be applied. However, the TENS treatment to the control group will be set so that no electricity will reach the patient.~A multimodal analgesia regimen will be applied postoperatively

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Description: Patients will receive 2 mg midazolam and 50 ug fentanyl for sedation before the block procedure. Each patient will be positioned appropriately, then a high-frequency linear array transducer (13-6 MHz) will be placed in the interscalene region to define the brachial plexus on the short axis. Under sterile conditions, 50 mm block needle will be advanced through the interscalene groove. After localization and negative aspiration, 15 ML of 5% bupivacaine drug will be injected into the interscalene area.~In the TENS applications on the painful area, 2 channels with 4 electrodes in the acute period will be applied. TENS device will be applied 4 times a day with treatment periods of 30 minutes.~A multimodal analgesia regimen will be applied postoperatively
Study: NCT06234202

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioactive Sleeve
Description: Pitchers will wear a bioactive sleeve immediately post-game through overnight.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioactive Sleeve
Description: Pitchers will wear a bioactive sleeve immediately post-game through overnight.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Sleeve
Description: Pitchers will wear a non-bioactive sleeve immediately post-game through overnight.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Sleeve
Description: Pitchers will wear a non-bioactive sleeve immediately post-game through overnight.
Study: NCT05961306

Intervention type: DIAGNOSTIC_TEST
Intervention: SCID 5
Description: SCID 5 is a semi-structured standard clinical interview. We will focus on current depressive episode, (hypo)manic episode, anxiety disorders, OCD and PTSD.~The interview will be conducted by phone.

Intervention type: DIAGNOSTIC_TEST
Intervention: SCID 5
Description: SCID 5 is a semi-structured standard clinical interview. We will focus on current depressive episode, (hypo)manic episode, anxiety disorders, OCD and PTSD.~The interview will be conducted by phone.
Study: NCT06044350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT4406F Injection
Description: Intravenous infusion; Dosage:500mg/time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT4406F Placebos
Description: Intravenous infusion; Dosage:500mg/time
Study: NCT06641193

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high frequency-repetitive transcranial magnetic stimulation
Description: rTMS involves the repeated application of magnetic pulses to specific areas of the brain. These pulses are delivered using a coil placed on the scalp, which generates a magnetic field that induces electrical currents in the brain tissue.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham stimulation
Description: The sham group receives 10 sessions of rTMS stimulation with a sham stimulation coil, which emits the same sound and vibration as the active coil but does not produce any induced electrical currents.
Study: NCT06053203

Intervention type: OTHER
Intervention: Exposure of interest - Moderate or High-risk Preeclampsia
Description: No intervention

Intervention type: OTHER
Intervention: Exposure of interest - Moderate or High-risk Preeclampsia
Description: No intervention

Intervention type: OTHER
Intervention: Exposure of interest - Moderate or High-risk Preeclampsia
Description: No intervention

Intervention type: OTHER
Intervention: Exposure of interest - Moderate or High-risk Preeclampsia
Description: No intervention
Study: NCT05587504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette with sweetness type 1 and pronation level 1
Description: An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 1 and protonation level 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette with sweetness type 1 and pronation level 2
Description: An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 1 and protonation level 2.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette with sweetness type 2 and pronation level 1
Description: An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 2 and protonation level 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette with sweetness type 2 and pronation level 2
Description: An open system ECIG (Kanger Sub Box Mini and/or a Kangertech Sub Box Mini tank connected to hardware and/or software to limit puff duration) set to 15 Watts, which will contain e-liquid that contains a predetermined mg/ml of nicotine and sweetness type 2 and protonation level 2.
Study: NCT05533957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of different dosages of oxygen therapy
Description: To evaluate the response (vasodilation, neuromuscular fatigue and muscle oxygenation) of the administration of different dosages of oxygen therapy (ie. FiO2) in patients with COPD associated with CRF and LTOT
Study: NCT04677556

Intervention type: OTHER
Group type: OTHER
Intervention: Esogastric pressures measurement
Description: Catheter placement : at least 2 hours after and within 24 hours following the initial ventilation support establishment (CPAP or NiPPV according to usual practice and clinical conditions). 2 periods of measurements : with the initial and with the 2nd ventilation support using a cross-over for each patient. For each period, the first serie of measurements will be carried out without modifying the settings of the support ( clinical setting), and the second one using esogastric pressures by adjusting the settings of the ventilation support in order to obtain an optimal normalization or reduction of the amplitude of the Pes and Pdi deltas (physiological setting). 5 minutes of spontaneous breathing with/without oxygen between period 1 and 2 (depending on the patient's conditions). All measurements will be performed for 5 minutes after a 15 minutes quiet breathing. After measurements, the optimal respiratory support will be continued.
Study: NCT06523556

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axatilimab
Description: Given IV
Study: NCT05967780

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group A: Patients with FHP receiving standard cardiac rehabilitation
Description: Consenting participants in this group will receive a standard cardiac rehabilitation protocol that includes preoperative education and post-operative exercises, chest physiotherapy, functional mobility and care. Phase 1 begins after the patient has been considered clinically compensated due to the optimization of the clinical treatment and/or the use of an interventional procedure. In this phase, a combination of low-intensity physical exercise (that includes range of motion exercises for upper \& lower extremities + progressive mobilization from sitting on bedside to walking short distance and up to stair climbing), incentive spirometry exercise, percussions, breathing exercises and effective coughing exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group B: Patients with FHP receiving standard cardiac rehabilitation + therapeutic exercises
Description: The participants who give consent will receive standard cardiac rehabilitation protocol (as Group A) with therapeutic exercise in the intervention group.~Therapeutic exercises will be delivered to the participant by treating physiotherapist in physical, verbal and written formats as individualized sessions on the ward 4 weeks before the surgery and keep him doing exercises under supervision while staying in the ward before surgery. A log will be provided to measure performance to ensure program compliance. After discharge from the hospital, the patient will continue exercises at home as performed and guided physically by the therapist and also in the exercises manual and flyer given to the patient. Patients will be instructed to follow therapeutic exercise for 4 weeks pre-operatively and 4 weeks postoperatively after discharge from the hospital.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group C: Patients without FHP receiving standard cardiac rehabilitation
Description: The participants without forward head posture will be included in this group and will receive same standard cardiac rehabilitation as the participants in group A.
Study: NCT06523556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary study
Study: NCT05829291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: Alpha DaRT Applicators (the Alpha Needle Applicator, the Alpha Flex Applicator, and the Alpha Plant Applicator) and radioactive sources named Alpha DaRT Seeds - Ra-224 coated onto stainless steel tubes inserted into the tumor. Collectively, the Alpha DaRT Applicators and Seeds are referred to as the Alpha DaRT Device.
Study: NCT06483555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2, intravenously on day 1 and day 15, for subjects with basal-like cell type pancreatic carcinoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m2 intravenously on day 1 and day 15 for subjects with basal-like cell type pancreatic carcinoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 50 mg per oral daily. for subjects with basal-like cell type pancreatic carcinoma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NALIRIFOX
Description: Subjects with classical pancreatic adenocarcinoma will receive. NALIRIFOX is liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin. Dosing and plan will be decided by the treating physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfirinox
Description: Subjects with classical pancreatic adenocarcinoma will receive. Dosing and plan will be decided by the treating physician.
Study: NCT05345379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single intervention
Description: Single intervention at the day of fixed orthodontic appliance bonding

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single intervention
Description: Single intervention at the day of fixed orthodontic appliance bonding
Study: NCT05787613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX26
Description: Anti-LAG-3 monoclonal Antibody Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX26
Description: Anti-LAG-3 monoclonal Antibody Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: anti-PD-1 humanized monoclonal antibody injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: anti-PD-1 humanized monoclonal antibody injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Serplulimab
Description: anti-PD-1 humanized monoclonal antibody injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: non-squamous NSCLC patients will receive Pemetrexed 500mg/m2, IV, Q3W. Carboplatin AUC 5mg/mL/min, IV, Q3W, up to 4 cycles.squamous NSCLC patients will receive Albumin-paclitaxel 100mg/m2, IV, Q1W or paclitaxel 175mg/m2, IV, Q3W and carboplatin AUC 5 mg/mL/min, IV, Q3W, up to 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: non-squamous NSCLC patients will receive Pemetrexed 500mg/m2, IV, Q3W. Carboplatin AUC 5mg/mL/min, IV, Q3W, up to 4 cycles.squamous NSCLC patients will receive Albumin-paclitaxel 100mg/m2, IV, Q1W or paclitaxel 175mg/m2, IV, Q3W and carboplatin AUC 5 mg/mL/min, IV, Q3W, up to 4 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy drug
Description: non-squamous NSCLC patients will receive Pemetrexed 500mg/m2, IV, Q3W. Carboplatin AUC 5mg/mL/min, IV, Q3W, up to 4 cycles.squamous NSCLC patients will receive Albumin-paclitaxel 100mg/m2, IV, Q1W or paclitaxel 175mg/m2, IV, Q3W and carboplatin AUC 5 mg/mL/min, IV, Q3W, up to 4 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04959487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food support
Description: 1. Diabetes-tailored food support. Project Open Hand will provide intervention participants six months of supplemental food support meeting on average 75% of their daily energy requirements. Food support will consist of a mix of meals tailored for T2DM, and T2DM-healthy groceries, consistent with American Diabetes Association (ADA) guidelines for diabetes healthy diets under the responsibility of a registered dietitian.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling and education
Description: 2. Nutritional counseling and education: The registered dietitian will provide individual nutritional counseling two times (at baseline and month 5-6) during the intervention. In addition, group-based DM nutrition education will be conducted over four 1-hour-long sessions. The nutrition education will be conducted by a POH dietitian, and the curriculum will be consistent with published diabetes self- management education principles, utilizing effective strategies in lower wealth, lower literacy populations.
Study: NCT06494969

Intervention type: DEVICE
Intervention: Intraocular pressure measurement
Description: Intraocular pressures were measured and recorded at 8 predefined time points using a tonometer; before anesthesia induction (T1), 10 min after induction (T2), immediately before the beginning of CPB (T3), 3 minute after the beginning of CPB (T4), 3 minute after cross-clamping (T5), 3min after cross-clamp removal (T6), immediately before the weaning of CPB (T7), and end of the surgery (immediately after skin closure) (T8).

Intervention type: DEVICE
Intervention: Intraocular pressure measurement
Description: Intraocular pressures were measured and recorded at 8 predefined time points using a tonometer; before anesthesia induction (T1), 10 min after induction (T2), immediately before the beginning of CPB (T3), 3 minute after the beginning of CPB (T4), 3 minute after cross-clamping (T5), 3min after cross-clamp removal (T6), immediately before the weaning of CPB (T7), and end of the surgery (immediately after skin closure) (T8).
Study: NCT05529459

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Coronary Intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous Coronary Intervention
Study: NCT06368427

Intervention type: DRUG
Intervention: budesonide / glycopyrronium / formoterol
Description: Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension.~The COnCORD study is an observational study that will be conducted in a real-life setting in Romania and is not designed to evaluate medicinal products given according to a specific randomised schedule. Treatment with BGF MDI treatment prescribed as per current practice, according to the SmPC and local market reimbursement criteria
Study: NCT06449651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nipocalimab
Description: Nipocalimab will be administrated intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administrated intravenously.
Study: NCT06288191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
Description: Dual inhibition of the distinct LAG3 and PD-1 checkpoint pathways
Study: NCT06202651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG Laser
Description: Prior to Nd:YAG laser treatment, two drops of topical anesthetic will be administered to the study eye. The two most peripheral deposits that are of ca. 50 µm size will be located and used as the targets for the treatment. The Nd:YAG laser will then be administered to each one of the two deposits, beginning with the lowest energy setting (0.3 mJ) and increasing the energy levels up to to 3 mJ in increments of 0.5 mJ. Five single-burst shots will be performed per laser energy setting per opacity until a visible effect is seen.~After the procedure, the eye will be examined to assess the integrity of the corneal epithelium. If a defect is seen, the participant will be advised to administer topical antibiotic eye drops three times daily for a week as a precautionary measure.
Study: NCT05858008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Subjects will be educated about the health benefits of time-restricted eating. Each subject will self-select a 10-hour (10hr +/- 1 hr) window aligned with their active phase during which they will consume all daily calories. Subjects will text the time of their first and last daily calories for the duration of the study.
Study: NCT04256954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer navigation intervention
Description: A peer navigator will assist those assigned to the intervention group access community mental health, medical care and substance use services. Peer navigators will help create linkages to services
Study: NCT04898634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-78278343
Description: JNJ-78278343 will be administered.
Study: NCT05029921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab will be administered as an IV injection in induction phase and as a SC injection in maintenance phase.
Study: NCT06544616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64042056
Description: JNJ-64042056 will be administered intramuscularly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intramuscularly.
Study: NCT04533750

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT06340360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezpegaldesleukin
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezpegaldesleukin
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous
Study: NCT05055063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: by vein over 30-60 minutes on Day 1 of each 56-day cycle for the first 6 cycles.
Study: NCT06511999

Intervention type: DEVICE
Intervention: Continuous SjO2 monitoring with a TriOx PICC catheter
Description: The TriOx PICC catheter is capable of continuous, indwelling measurement of venous oxygen saturation, which is displayed on a bedside monitor connected by an optical cable. Enrolled participants will undergo continuous SjO2 measurement for 72 hours. Clinical care will not be directed by the continuous SjO2 values.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intermittent SjO2 monitoring with a TriOx PICC catheter
Description: The TriOx PICC catheter is also capable of intermittent blood sampling enabling measurement of SjO2 on a laboratory blood gas analyzer. Enrolled participants will undergo intermittent SjO2 measurement every 4-6 hours for 72 hours. Clinical care will be directly by the intermittent values.
Study: NCT05297786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab Injection [Takhzyro]
Description: Lanadelumab 300 mg subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection
Study: NCT05915988

Intervention type: DEVICE
Group type: OTHER
Intervention: UNEEG EpiSight solution
Description: Implantation subcutis under local anesthetics